Answers are grounded in this paper and cite their sources.
Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
No takes yet. Share an insight, caveat, or question.
Eickhoff et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: